Celgene
 |
|
| Public | |
| Traded as | |
| Industry | Biotechnology |
| Founded | 1986 |
| Headquarters | Summit, New Jersey, U.S. |
|
Key people
|
Robert J. Hugin (Executive Chairman) Sol J. Barer (Founder) Mark Alles (CEO) |
| Products | Thalomid Revlimid Abraxane Pomalyst/Imnovid Otezla |
| Revenue |
|
|
|
|
|
| Total assets |
|
| Total equity |
|
|
Number of employees
|
4,182 (December 2010) |
| Website | www |
US$ 6.4939 billion (2013)
US$ 1.4499 billion (2013)Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.
Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.
For acquisitions history, see section below "Company origin and acquisition history", and for product-related history, see section below "Product-related history".
In 2010 Celgene looked to relocate its UK headquarters from Riverside House in Windsor to a new development Stockley Park, Uxbridge.
In January 2012, Celgene and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc. Under the terms of the merger agreement, Celgene will acquire Avila Therapeutics, Inc. for $350 million in cash, plus up to $195 million for milestones contingent upon the development and regulatory approval of AVL-292, as well as up to $380 million in potential milestone payments contingent upon the development and approval of candidates generated from the Avilomics platform.
Citing a market capitalization of US$67 billion, and stock appreciation of 107%, Celgene was Forbes Magazine's number 2 ranked drug company of 2013.
In 2014, Celgene and OncoMed Pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompassing demcizumab and five other biologics from OnoMed's pipeline.
...
Wikipedia